कृपया अन्य खोज का प्रयास करें
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Jae Soo Shin | - | 2018 | Member of Advisory Board |
Hyun Soo Lee | - | 2018 | Member of Advisory Board |
Sang Goo Kim | 57 | 2015 | Independent Director |
Heon Ju Lee | - | 2018 | Member of Advisory Board |
Konstantin Lichtenwald | 39 | 2018 | CFO, Corporate Secretary & Director |
Yee Sing Cheng | 42 | 2023 | CEO & Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है